US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Zevra Therapeutics, Inc. - Common Stock (NQ:ZVRA)

10.70 +0.71 (+7.11%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zevra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Zevra Therapeutics Q2 Earnings Call Highlights ↗
Zevra Therapeutics (NASDAQ:ZVRA) reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C... 
Via MarketBeat
Topics Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
From Levi & Korsinsky, LLP
Via Business Wire
Zevra Therapeutics (NASDAQ:ZVRA) Shares Surge After Blowout Q1 Earnings Beat ↗
Via Chartmill
Zevra Therapeutics Inc (NASDAQ:ZVRA) Stock Surges 21% After Blowing Past Q4 Earnings Estimates ↗
Via Chartmill
News headline image
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
These stocks are gapping in today's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Zevra (ZVRA) Q1 2026 Earnings Call Transcript ↗
Zevra (ZVRA) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Why Zevra Therapeutics Stock Zoomed 21% Higher Today ↗
The biotech made a dramatic flip into profitability in its final quarter of 2025. 
Via The Motley Fool
Gapping stocks in Tuesday's session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Turn Green On Iran War De-Escalation Signals: Why NVDA, ORCL, JOBY, VRTX, ZVRA Are On Traders' Radar Today ↗
Data from Stocktwits indicated that retail sentiment on SPY and QQQ was stabilizing. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
Dow, S&P 500, Nasdaq Futures Dip After Wall Street Rebound: Why SLS, ZVRA, RLMD, USO, CASY Are Trending After-Hours ↗
Oil whipsawed, with WTI briefly topping $119 before plunging toward the low $80s as Trump said the Iran war could end soon. 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
ZVRA Stock Soars On Upbeat Q4 Results, Optimism For EMA Approval Of Niemann-Pick Disease Treatment ↗
For the fourth quarter, Zevra announced net revenue of $34.1 million, exceeding an analyst estimate of $28.05 million. 
Via Stocktwits
Top movers in Monday's after hours session ↗
Via Chartmill
News headline image
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
From Johnson Fistel, PLLP
Via Business Wire
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Zevra (ZVRA) Q3 2025 Earnings Call Transcript ↗
Zevra (ZVRA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. 
Via Benzinga
News headline image
Zevra Therapeutics' Stock Soars on Strong Performance and Strategic Wins: What It Means for Investors
Zevra Therapeutics (NASDAQ: ZVRA) has captured significant attention in the financial markets with its recent robust stock performance and a compelling "Strong" Relative Strength Rating. As of early... 
Via MarketMinute
News headline image
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket ↗
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks — Zevra Therapeutics, Inc. (NASDAQGS: ZVRA) to Present New MIPLYFFA Data at ICIEM, Poster Earns Best Poster Award
Via Investor Brand Network
News headline image
Crude Oil Down 1%; Performance Food Group Earnings Top Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
< Previous 1 2 3 Next >